Related Experiment Video
Updated: Aug 18, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
[Angiogenesis and anti-angiogenic strategies for glioblastoma]
Sophie de Boüard1, Jean-Sébastien Guillamo
1Groupe régional d'étude sur le cancer (Grecan), Université de Caen Basse-Normandie, Centre François-Baclesse, avenue du Général-Harris, 14076 Caen Cedex 05. s.de.bouard@baclesse.fr
Abstract:
The poor prognosis of patients with glioblastoma multiforme in spite of aggressive conventional anticancer therapies has led to the search for new therapeutic strategies. As glioblastomas are highly vascularized and their growth is angiogenesis-dependent, the inhibition of the sprouting of new capillaries from preexisting blood vessels is one of the most promising therapeutic approaches. Different anti-angiogenic strategies have been developed: inhibition of pro-angiogenic factors and/or receptors and/or downstream cell signaling, inactivation of endothelial cells, inhibition of cellular adhesion molecules and/or extracellular matrix remodeling. Inhibitors of angiogenesis are separated into endogenous inhibitors such as angiostatin, trombospondin or alpha interferon and natural or synthetic inhibitors such as thalidomide, antibodies against angiogenic growth factors or inhibitors of tyrosine kinase receptors. In this review, the majority of experimental studies in glioblastoma models in vivo are summarized and clinical perspectives are discussed.
Insights
Glioblastoma multiforme (GBM) treatment is challenging due to poor prognosis. Inhibiting tumor angiogenesis, the growth of new blood vessels, offers a promising therapeutic strategy for GBM.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Therapeutics
Context:
- Glioblastoma multiforme (GBM) exhibits poor prognosis despite conventional therapies.
- GBM is highly vascularized and its growth is angiogenesis-dependent.
Purpose:
- To review novel therapeutic strategies targeting angiogenesis in GBM.
- To summarize experimental studies and discuss clinical perspectives of anti-angiogenic therapies for GBM.
Summary:
- Anti-angiogenic strategies include inhibiting pro-angiogenic factors, receptors, downstream signaling, endothelial cells, or matrix remodeling.
- Inhibitors are categorized as endogenous (e.g., angiostatin) or synthetic/natural (e.g., thalidomide, anti-VEGF antibodies, tyrosine kinase inhibitors).
- This review synthesizes in vivo glioblastoma model studies and explores clinical applications of these inhibitors.
Impact:
- Highlights the potential of anti-angiogenic therapies to improve GBM patient outcomes.
- Provides a comprehensive overview of current and future therapeutic directions for GBM.
- Facilitates research and clinical development of targeted GBM treatments.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply